1. Pink Sheet
  2. >>Regulatory Trackers

Adu-CAN-umab? Reading The Tea Leaves For Biogen’s US Filing For Alzheimer’s Drug

 
• By Michael McCaughan

The US Food and Drug Administration is expediting the review for Biogen’s Alzheimer’s therapy aducanumab, setting up a likely November/December advisory committee consideration that in normal times would be the dominant topic for those who care about the agency.

Priority Stamp
The US FDA has made clear the review of Biogen's aducanumab application is a priority, but is it approvable? • Source: Shutterstock

In normal times, everyone who cares about the US Food and Drug Administration would be frantically focusing on its plans for a very high-profile advisory committee meeting likely to take place before the end of the year.

COVID-19 vaccines? No, we’re talking about a likely Peripheral and Central Nervous Systems Drugs Advisory Committee meeting to review

More from US FDA Performance Tracker

More from Regulatory Trackers